Surgical Science Sweden (SUS.ST) Stock Price

Surgical Science Sweden Price

OMX·CLOSED
48.40SEK+11.10 (+25.90 %)
Market closed

Over the last 11 years Surgical Science Sweden grew revenue by 33.6% annually, reaching 992.34 M SEK. Earnings per share have grown at 21.3% per year over the last 9 years. For Surgical Science Sweden, the net margin of 6.7% is down versus 23.5% a few years ago. The consensus 12-month price target for Surgical Science Sweden is 61.20 SEK, about 26.4% above where the stock trades today. Of 8 analysts, 5 rate the stock a buy — an overall Buy consensus. The stock trades about 102% above its 52-week low.

Surgical Science Sweden stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Surgical Science Sweden over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Surgical Science Sweden stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Surgical Science Sweden's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Surgical Science Sweden Stock Price History
DateSurgical Science Sweden Price
8/19/202648.40 SEK
8/17/202637.30 SEK
8/14/202638.20 SEK
8/13/202637.28 SEK
8/12/202637.72 SEK
8/11/202638.52 SEK
8/10/202638.12 SEK
8/7/202637.10 SEK
8/6/202635.00 SEK
8/5/202635.12 SEK
8/4/202634.82 SEK
7/31/202634.58 SEK
7/30/202634.70 SEK
7/29/202633.94 SEK
7/28/202632.88 SEK
7/27/202632.62 SEK
7/24/202630.84 SEK
7/23/202630.20 SEK
7/22/202630.36 SEK
7/21/202630.40 SEK
7/20/202630.30 SEK
7/17/202630.02 SEK
7/15/202630.22 SEK
7/14/202630.62 SEK
7/13/202631.02 SEK
7/10/202630.76 SEK
7/9/202630.70 SEK
7/8/202629.98 SEK
7/7/202631.62 SEK
7/6/202631.64 SEK
7/3/202632.54 SEK
7/2/202632.94 SEK
7/1/202632.46 SEK
6/30/202631.74 SEK
6/29/202632.50 SEK
6/26/202631.56 SEK
6/25/202631.68 SEK
6/24/202631.04 SEK
6/23/202631.20 SEK
6/22/202631.62 SEK
6/18/202630.80 SEK
6/17/202631.20 SEK
6/16/202631.22 SEK
6/15/202632.88 SEK
6/12/202632.62 SEK
6/11/202632.20 SEK
6/10/202632.62 SEK
6/9/202632.34 SEK
6/8/202633.28 SEK
6/5/202633.88 SEK
6/4/202635.20 SEK
6/3/202633.32 SEK
6/2/202633.72 SEK
6/1/202635.02 SEK
5/29/202636.36 SEK
5/28/202635.70 SEK
5/27/202636.02 SEK
5/26/202635.34 SEK
5/25/202637.40 SEK
5/22/202638.00 SEK
5/21/202637.42 SEK
5/20/202637.58 SEK
5/19/202633.32 SEK
5/18/202633.10 SEK
5/15/202631.58 SEK
5/13/202632.54 SEK
5/12/202633.14 SEK
5/11/202633.14 SEK
5/8/202633.10 SEK
5/7/202634.00 SEK
5/6/202633.26 SEK
5/5/202633.52 SEK
5/4/202634.18 SEK
4/30/202632.82 SEK
4/29/202632.52 SEK
4/28/202632.92 SEK
4/27/202633.40 SEK
4/24/202633.50 SEK
4/23/202634.54 SEK
4/22/202636.12 SEK
4/21/202635.64 SEK
4/20/202635.90 SEK
4/17/202636.86 SEK
4/16/202636.00 SEK
4/15/202635.14 SEK
4/14/202634.34 SEK
4/13/202632.16 SEK
4/10/202631.64 SEK
4/9/202631.50 SEK
4/8/202631.06 SEK
4/7/202631.20 SEK
4/2/202632.42 SEK
4/1/202631.92 SEK
3/31/202630.38 SEK
3/30/202629.44 SEK
3/27/202630.04 SEK
3/26/202630.70 SEK
3/25/202630.96 SEK
3/24/202630.70 SEK
3/23/202630.64 SEK
3/20/202630.46 SEK
3/19/202631.54 SEK
3/18/202632.34 SEK
3/17/202632.40 SEK
3/16/202632.00 SEK
3/13/202631.50 SEK
3/12/202631.70 SEK
3/11/202632.22 SEK
3/10/202631.62 SEK
3/9/202631.44 SEK
3/6/202632.04 SEK
3/5/202632.60 SEK
3/4/202633.04 SEK
3/3/202630.18 SEK
3/2/202631.18 SEK
2/27/202632.30 SEK
2/26/202632.70 SEK
2/25/202631.32 SEK
2/24/202631.82 SEK
2/23/202632.32 SEK
2/20/202632.90 SEK
2/19/202629.10 SEK
2/18/202624.88 SEK
2/17/202624.74 SEK
2/16/202625.04 SEK
2/13/202625.92 SEK
2/12/202624.72 SEK
2/11/202623.92 SEK
2/10/202625.00 SEK
2/9/202624.18 SEK
2/6/202624.64 SEK
2/5/202624.28 SEK
2/4/202624.64 SEK
2/3/202625.94 SEK
2/2/202626.60 SEK
1/30/202627.02 SEK
1/29/202627.24 SEK
1/28/202628.52 SEK
1/27/202628.06 SEK
1/26/202628.42 SEK
1/23/202628.20 SEK
1/22/202628.32 SEK
1/21/202627.88 SEK
1/20/202629.30 SEK
1/19/202629.24 SEK
1/16/202630.60 SEK
1/15/202631.00 SEK
1/14/202631.24 SEK
1/13/202632.00 SEK
1/12/202631.90 SEK
1/9/202631.60 SEK
1/8/202631.20 SEK
1/7/202630.72 SEK
1/5/202630.14 SEK
1/2/202631.04 SEK
12/30/202532.50 SEK
12/29/202531.96 SEK
12/23/202532.06 SEK
12/22/202531.98 SEK
12/19/202531.56 SEK
12/18/202531.98 SEK
12/17/202532.52 SEK
12/16/202533.18 SEK
12/15/202533.60 SEK
12/12/202533.92 SEK
12/11/202534.04 SEK
12/10/202533.76 SEK
12/9/202533.58 SEK
12/8/202532.60 SEK
12/5/202533.52 SEK
12/4/202534.74 SEK
12/3/202533.12 SEK
12/2/202533.10 SEK
12/1/202534.40 SEK
11/28/202533.96 SEK
11/27/202532.08 SEK
11/26/202530.08 SEK
11/25/202530.08 SEK
11/24/202529.36 SEK
11/21/202529.62 SEK
11/20/202528.58 SEK
11/19/202528.38 SEK
11/18/202527.91 SEK
11/17/202529.10 SEK
11/14/202529.28 SEK
11/13/202529.76 SEK
11/12/202533.75 SEK
11/11/202533.29 SEK
11/10/202532.57 SEK
11/7/202532.21 SEK
11/6/202532.97 SEK
11/5/202532.49 SEK
11/4/202533.45 SEK
11/3/202533.09 SEK
10/31/202533.69 SEK
10/30/202533.69 SEK
10/29/202533.97 SEK
10/28/202534.27 SEK
10/27/202535.43 SEK
10/24/202535.88 SEK
10/23/202535.96 SEK
10/22/202536.50 SEK
10/21/202535.55 SEK
10/20/202534.81 SEK
10/17/202533.89 SEK
10/16/202534.47 SEK
10/15/202534.39 SEK
10/14/202533.87 SEK
10/13/202534.55 SEK
10/10/202535.09 SEK
10/9/202536.80 SEK
10/8/202535.29 SEK
10/7/202535.31 SEK
10/6/202536.06 SEK
10/3/202536.32 SEK
10/2/202536.46 SEK
10/1/202535.33 SEK
9/30/202535.27 SEK
9/29/202535.45 SEK
9/26/202535.71 SEK
9/25/202534.89 SEK
9/24/202535.69 SEK
9/23/202536.10 SEK
9/22/202536.32 SEK
9/19/202536.88 SEK
9/18/202537.12 SEK
9/17/202535.86 SEK
9/16/202537.44 SEK
9/15/202536.70 SEK
9/12/202537.14 SEK
9/11/202536.40 SEK
9/10/202537.02 SEK
9/9/202537.20 SEK
9/8/202537.50 SEK
9/5/202537.88 SEK
9/4/202537.26 SEK
9/3/202537.66 SEK
9/2/202538.14 SEK
9/1/202538.90 SEK
8/29/202538.70 SEK
8/28/202539.75 SEK
8/27/202540.11 SEK
8/26/202541.11 SEK
8/25/202543.23 SEK
8/22/202542.39 SEK
Access this data via the Eulerpool API
Get Free API Key

Surgical Science Sweden Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
882.85 M SEK
189.15 M SEK
233.97 M SEK
Jan 1, 2024
884.09 M SEK
144.32 M SEK
131.65 M SEK
Jan 1, 2025
992.34 M SEK
108.97 M SEK
66.82 M SEK
Jan 1, 2026 (e)
987.48 M SEK
222.24 M SEK
98.23 M SEK
Jan 1, 2027 (e)
1.10 B SEK
248.46 M SEK
138.66 M SEK
Jan 1, 2028 (e)
1.23 B SEK
276.88 M SEK
172.60 M SEK
Jan 1, 2029 (e)
1.46 B SEK
328.25 M SEK
250.54 M SEK
Jan 1, 2030 (e)
1.63 B SEK
367.61 M SEK
296.97 M SEK

Surgical Science Sweden Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 21, 2026, 7:47 PM
 
REVENUEB SEK
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM SEK
EBITM SEK
EBIT MARGIN%
NET INCOMEM SEK
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0.050.050.060.070.100.100.370.800.880.880.990.991.101.231.461.63
12.2010.8711.7614.0455.382.97251.92119.139.980.2312.22-0.5011.7511.5118.5412.00
113.04113.73108.77109.2382.1884.6272.4066.2169.3967.5358.0658.0658.0658.0658.0658.06
52.0058.0062.0071.0083.0088.00265.00531.00612.00597.00576.00573.10640.45714.19846.58948.19
1.00–-4.00-4.0015.0019.0088.00162.00189.00144.00108.00222.00248.00276.00328.00367.00
2.17–-7.02-6.1514.8518.2724.0420.2021.4316.2910.8922.4922.4822.4422.5022.47
1.003.00-2.00-4.0012.0015.0086.00187.00233.00131.0066.0098.00138.00172.00250.00296.00
-133.33200.00-166.67100.00-400.0025.00473.33117.4424.60-43.78-49.6248.4840.8224.6445.3518.40
51.0314.3224.3224.3230.5234.4942.6750.9051.0351.0351.0351.0351.0351.0351.0351.03
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Surgical Science Sweden generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Surgical Science Sweden retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Surgical Science Sweden's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Surgical Science Sweden has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Surgical Science Sweden's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Surgical Science Sweden stock margins

The Surgical Science Sweden margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Surgical Science Sweden. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Surgical Science Sweden.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
72.51 %
24.20 %
23.52 %
Jan 1, 2022
66.23 %
20.25 %
23.42 %
Jan 1, 2023
69.42 %
21.43 %
26.50 %
Jan 1, 2024
67.63 %
16.32 %
14.89 %
Jan 1, 2025
58.14 %
10.98 %
6.73 %
Jan 1, 2026 (e)
58.14 %
22.51 %
9.95 %
Jan 1, 2027 (e)
58.14 %
22.51 %
12.56 %
Jan 1, 2028 (e)
58.14 %
22.51 %
14.03 %

Surgical Science Sweden Stock Revenue, EBIT, Earnings per Share

The Surgical Science Sweden earnings per share therefore indicates how much revenue Surgical Science Sweden has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
8.60 SEK
2.08 SEK
2.02 SEK
Jan 1, 2022
15.77 SEK
3.19 SEK
3.69 SEK
Jan 1, 2023
17.30 SEK
3.71 SEK
4.59 SEK
Jan 1, 2024
17.33 SEK
2.83 SEK
2.58 SEK
Jan 1, 2025
19.45 SEK
2.14 SEK
1.31 SEK
Jan 1, 2026 (e)
19.35 SEK
4.36 SEK
1.93 SEK
Jan 1, 2027 (e)
21.63 SEK
4.87 SEK
2.72 SEK
Jan 1, 2028 (e)
24.11 SEK
5.43 SEK
3.38 SEK

Surgical Science Sweden business model & stock analysis

Surgical Science Sweden AB is a Swedish company specializing in the development and manufacturing of medical simulators for training professionals in the medical industry. The company was founded in 1999 by a team of doctors, engineers, and scientists and is headquartered in Gothenburg. Since then, the company has constantly expanded and now has several branches around the world, including in the USA, Germany, and Hong Kong. Due to its innovative products and high-quality standards, the company is globally recognized and has received numerous awards. Surgical Science Sweden AB offers a wide range of simulators for various medical disciplines, including surgery, anesthesia, obstetrics, and pediatrics. They offer both hardware and software-based solutions that allow trainees to practice complex procedures and interventions in a safe environment. The company's business model is based on the belief that simulation is crucial for the training of medical professionals to ensure the highest quality and safety for patients. By simulating realistic situations, trainees can gain valuable experience before working in the real practice. Surgical Science Sweden AB has a range of products targeting various areas of medical education. One of their most well-known simulators is the LaparoSculptor, which was specifically developed for training in minimally invasive surgery. The simulator can perform various procedures such as gallbladder and hernia operations, offering both physical and virtual options. Another product is the ObstetricSim, a simulator for obstetric training. The simulator fully simulates the conditions of a normal birth, including the stages of labor and delivery. It also includes rare complications such as shoulder dystocia and umbilical cord prolapse. Surgical Science Sweden AB has also developed simulators focusing on the training of anesthesiologists. The simulator in this area is the ANTS (Anesthesia Simulator), which trains trainees in the proper use of anesthetics, patient observation, and managing emergencies during anesthesia issues. In addition to developing hardware and software solutions, the company also focuses on continuous improvement and development of its products. Surgical Science Sweden AB works closely with leading medical specialists to ensure that the simulator meets the latest requirements and best practices. The company is also willing to rent or sell the simulators and its expertise to medical institutions, providing a broader audience with the opportunity to benefit from the technology. In conclusion, Surgical Science Sweden AB makes a significant contribution to the training of medical professionals and thereby contributes to improving patient health worldwide with its innovative and high-quality simulators. By combining the latest technology, industry expertise, and a constant focus on customer needs, the company continuously strives for excellence and innovation.

Surgical Science Sweden SWOT Analysis

Strengths

  • Established presence in the medical simulation industry
  • Strong research and development capabilities
  • High-quality and innovative product portfolio
  • Experienced and knowledgeable management team

Weaknesses

  • Relatively small market share compared to major competitors
  • Limited global distribution network
  • Dependence on third-party suppliers for certain components
  • Higher product prices compared to some competitors

Opportunities

  • Increasing demand for medical simulation solutions
  • Expansion into emerging markets with growing healthcare sectors
  • Collaboration opportunities with renowned medical institutions
  • Development of new simulation technologies

Threats

  • Intense competition from established simulation companies
  • Regulatory challenges in different markets
  • Economic downturn affecting healthcare spending
  • Potential disruptive technologies impacting the industry

Surgical Science Sweden Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Surgical Science Sweden historical P/E ratio, EBIT multiple, and P/S ratio

Surgical Science Sweden annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Surgical Science Sweden shares outstanding

The number of shares of Surgical Science Sweden was 51.03 M in 2025. This indicates how many shares Surgical Science Sweden is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
42.67 M Stocks
Jan 1, 2022
50.90 M Stocks
Jan 1, 2023
51.03 M Stocks
Jan 1, 2024
51.03 M Stocks
Jan 1, 2025
51.03 M Stocks
Jan 1, 2026 (e)
51.03 M Stocks
Jan 1, 2027 (e)
51.03 M Stocks
Jan 1, 2028 (e)
51.03 M Stocks

Surgical Science Sweden stock splits

In Surgical Science Sweden's history, there have been no stock splits.

Current Surgical Science Sweden forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
62.50 % (5)
Hold
37.50 % (3)
Sell
0.00 % (0)
12M Price Target
61.20
Last Price
49.30
Currency
SEK
12M Return Potential
24.14 %
LTM Return
0 %

Surgical Science Sweden Earnings Calls

2025

Surgical Science Sweden Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/14/20241.01SEK-275.73 MSEK-2024 Q1
2/21/20241.20SEK-271.94 MSEK-2023 Q4
8/23/20230.71SEK-222.28 MSEK-2023 Q2
5/9/20230.61SEK-188.79 MSEK-2023 Q1
2/14/20231.01SEK-242.58 MSEK-2022 Q4
11/10/20220.63SEK-193.36 MSEK-2022 Q3
8/25/20220.51SEK-168.49 MSEK-2022 Q2
5/11/20220.40SEK-152.25 MSEK-2022 Q1
2/16/20220.56SEK-151.24 MSEK-2021 Q4
11/10/20210.20SEK-69.02 MSEK-2021 Q3

Surgical Science Sweden shareholder structure

% Name
1.32667%
Schroder Investment Management (Europe) S.A.
Schroder Investment Management (Europe) S.A.
0.71780%
Case Kapitalförvaltning AB
Case Kapitalförvaltning AB
0.62155%
Skandia Investment Management AB
Skandia Investment Management AB
0.33159%
Montanaro Asset Management Limited
Montanaro Asset Management Limited
0.31022%
DNB Asset Management AS
DNB Asset Management AS
0.10783%
Aktia Wealth Management Ltd
Aktia Wealth Management Ltd

Surgical Science Sweden Beneficial Ownership Filings (SEC 13D/G)

Free Float
72.6%
Float Shares
-
Shares Outstanding
-

Surgical Science Sweden Executives and Management Board

14 members · avg. age 57 · 21 % women

Management

TE

Mr. Tom Englund (48)

Chief Executive Officer

–
AA

Ms. Anna Ahlberg (54)

Chief Financial Officer

–
RB

Mr. Ran Bronstein (59)

President - Research and Development

–
BT

Mr. Boaz Tal (55)

Chief Operating Officer

–
DZ

Mr. Doron Zilberman (61)

Executive Vice President of International Sales

–
IM

Ms. Inbal Mazor (54)

Executive Vice President Products and Marketing

–

Board of Directors

GH

Mr. Gisli Hennermark (52)

Director · since 2015

5.22 M SEK
JB

Mr. Jan Bengtsson (79)

Director · since 2005

–
TE

Mr. Thomas Eklund (58)

Independent Director

–
HF

Mr. Henrik Falconer (50)

Independent Director

–
TF

Mr. Tommy Forsell (70)

Independent Director · since 2019

–
EH

Ms. Elisabeth Hansson (48)

Independent Director

–

Frequently asked questions about Surgical Science Sweden

The business model of Surgical Science Sweden AB revolves around providing advanced medical simulation solutions. As a leading global supplier, Surgical Science focuses on developing and delivering high-fidelity simulators and software tools for medical training and education. These simulation solutions enable medical professionals to practice surgical procedures and enhance their skills in a safe and realistic environment. With a strong commitment to innovation and educational excellence, Surgical Science Sweden AB aims to improve patient safety and quality of care by offering state-of-the-art simulation technology to healthcare institutions and professionals worldwide.

Surgical Science Sweden AB is primarily active in the healthcare industry.

The main competitors of Surgical Science Sweden AB in the market include other companies operating in the medical simulation industry. These competitors may include Simulab Corporation, CAE Healthcare, Mentice AB, and Limbs & Things Ltd. These companies offer similar products and solutions for medical training and simulation purposes, competing with Surgical Science Sweden AB in terms of product quality, pricing, and market share. Surgical Science Sweden AB strives to maintain its competitive edge by continually innovating and delivering high-quality medical simulation technology to its customers.

Surgical Science Sweden AB is a company with a rich history and background. Established in Sweden, the company has been a prominent player in the field of surgical simulation and training since its inception. With a focus on providing realistic and immersive training solutions for medical professionals, Surgical Science Sweden AB has developed cutting-edge technology and advanced simulators. Over the years, the company has gained recognition for its innovation, quality, and commitment to improving surgical education. With a strong presence in the global market, Surgical Science Sweden AB continues to lead the way in revolutionizing surgical training, ensuring safer and more efficient procedures for healthcare professionals worldwide.

Surgical Science Sweden AB has achieved significant milestones in its journey. The company has made remarkable advancements in the field of surgical simulation, providing cutting-edge training solutions to medical professionals worldwide. Surgical Science Sweden AB has received recognition for its high-quality simulators, which offer a realistic and immersive experience for trainees. The company's commitment to innovation has led to partnerships with renowned medical institutions, paving the way for research collaborations and improved training methods. Additionally, Surgical Science Sweden AB has expanded its global presence, establishing itself as a leader in surgical education.

Surgical Science Sweden AB is primarily present in several countries and regions worldwide. The company has a global presence, with a strong focus on Scandinavia, Europe, North America, and Asia. Surgical Science Sweden AB has established partnerships and collaborations with numerous medical institutions, universities, and healthcare providers in these regions, ensuring the widespread availability and adoption of their cutting-edge surgical simulators and training solutions. With their commitment to excellence and innovation, Surgical Science Sweden AB continues to expand its reach, delivering advanced medical training technology to professionals in various countries and regions across the globe.

Surgical Science Sweden AB represents a set of core values and corporate philosophy that drive its operations. The company prioritizes excellence in healthcare simulation technology, aiming to enhance medical training and patient safety worldwide. Surgical Science Sweden AB is committed to providing innovative and advanced solutions for surgical education, offering realistic simulators that mimic the human anatomy and empower medical professionals to develop their skills and expertise. With a focus on quality, the company strives for continuous improvement and collaboration with industry partners, ensuring its products are at the forefront of medical simulation. Surgical Science Sweden AB's dedication to delivering superior training tools makes it a trusted leader in the field.

Analysts currently set an average price target of 63.24 SEK for the Surgical Science Sweden stock (median: 61.20 SEK), implying +28.3 % versus the latest price. The consensus is based on 8 analyst ratings.

Surgical Science Sweden Analyst Price Targets 2026

8 analysts currently rate the Surgical Science Sweden stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Surgical Science Sweden to generate revenue of 987.48 M SEK and earnings per share of 1.92 SEK.

Surgical Science Sweden Analyst Price Targets 2026

Converted at the current exchange rate, the Surgical Science Sweden share trades at 4.37 EUR (48.40 SEK).

The Surgical Science Sweden share (SUS.ST) is listed on 7 stock exchanges, including: Frankfurt (4P41.F), München (4P41.MU), Düsseldorf (4P41.DU), London (0AAU.L).

The company Surgical Science Sweden AB is an innovative company in the field of medical education. Founded in 1999, the company aims to improve the training of medical personnel by producing realistic simulators. The company places great emphasis on attention to detail and realistic simulation in order to ensure a high training quality. Surgical Science Sweden AB's business model is based on three areas of business: 1. Medical simulators Surgical Science Sweden AB produces a wide range of medical simulators that support the training of medical personnel in various areas. These include simulators for endovascular procedures, minimally invasive procedures, anesthesia, and resuscitation. The simulators are designed to be realistic and equipped with various scenarios to provide an effective training experience. 2. Training programs In addition to manufacturing medical simulators, Surgical Science Sweden AB also offers training programs tailored to the respective simulators. The training is provided by experienced instructors who support trainees in working with the simulators and provide feedback on their training. These training programs are an effective way to bring medical personnel up to date with the latest technology or acquire specific skills. 3. Maintenance and support Surgical Science Sweden AB also offers maintenance and support services for its medical simulators. These services are important to ensure that the simulators are always in perfect condition and ready for use at any time. In addition, the company also offers training in the use of the simulators and first-class technical support. Overall, Surgical Science Sweden AB has developed an innovative business model based on the production of realistic medical simulators, while also enabling high-quality training for medical personnel. The company has achieved its market position through a consistent focus on quality and innovation. The simulators from Surgical Science Sweden AB are used in leading medical training institutions worldwide, contributing to the improvement of medical personnel training and patient safety.

The expected revenue of Surgical Science Sweden is 987.48 M SEK. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Surgical Science Sweden is 98.23 M SEK. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Surgical Science Sweden is currently 25.14. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Surgical Science Sweden stock.

The price-to-sales ratio (P/S) of Surgical Science Sweden is currently 2.50. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Surgical Science Sweden stock.

The Eulerpool Quality Score for Surgical Science Sweden is 6/10.

The ISIN of Surgical Science Sweden is SE0014428512. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Surgical Science Sweden is A2P46G. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Surgical Science Sweden is SUS.ST. The ticker symbol is used to trade Surgical Science Sweden shares on the stock exchange.

Surgical Science Sweden paid dividends every year for the past 0 years.

Surgical Science Sweden is assigned to the 'Health' sector.

The dividends of Surgical Science Sweden are distributed in SEK.

All fundamentals and in-depth analysis of Surgical Science Sweden

Our stock analysis for Surgical Science Sweden stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Surgical Science Sweden. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Surgical Science Sweden Stock
Surgical Science Sweden Revenue→
Surgical Science Sweden Stock
Surgical Science Sweden Net Income→
Surgical Science Sweden Stock
Surgical Science Sweden P/E→
Surgical Science Sweden Stock
Surgical Science Sweden P/S→
Surgical Science Sweden Stock
Surgical Science Sweden EBIT→
Surgical Science Sweden Stock
Surgical Science Sweden Dividend→
Surgical Science Sweden Stock
Surgical Science Sweden Directors Dealings→
Surgical Science Sweden Stock
Surgical Science Sweden Stocks→
Surgical Science Sweden Stock
Surgical Science Sweden Market capitalization→
Surgical Science Sweden Stock
Surgical Science Sweden Debt→
Surgical Science Sweden Stock
Surgical Science Sweden Liabilities→
Surgical Science Sweden Stock
Surgical Science Sweden Equity→
Surgical Science Sweden Stock
Surgical Science Sweden AAQS→
Surgical Science Sweden Stock
Surgical Science Sweden Employees→
Surgical Science Sweden Stock
Surgical Science Sweden ROE→
Surgical Science Sweden Stock
Surgical Science Sweden ROA→
Surgical Science Sweden Stock
Surgical Science Sweden ROCE→
Surgical Science Sweden Stock
Surgical Science Sweden News→
Surgical Science Sweden Stock
Surgical Science Sweden Analyst Price Targets→

Health Stocks

SurgLine InternationalSurgical Innovations GroupSurrozenSurgery PartnersSusmedSupriya LifescienceSutro BiopharmaSupha PharmachemSuven Life SciencesSupernus PharmaceuticalsSuzhou Basecare Medical CorpSunwels CoAll Stocks A–Z →